Savara Inc (SVRA):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Savara Inc (SVRA) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7100
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Savara Inc (Savara) formerly Mast Therapeutics Inc is a clinical stage biopharmaceutical company, which develops therapies for the treatment of rare respiratory diseases, including cystic fibrosis (CF), and pulmonary alveolar proteinosis (PAP). The company’s lead product candidates include Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of treatment of PAP; and AeroVanc, an inhaled formulation of vancomycin for the treatment of CF. Its development pipeline also includes Aironite, a sodium nitrite solution for intermittent inhalation for the treatment of heart failure. The company has subsidiaries in the US and Denmark. Savara is headquartered in Austin, Texas, the US.

Savara Inc (SVRA) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Savara Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Savara Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Savara Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Savara Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Savara Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Savara Inc, Medical Equipment, Deal Details 10
Venture Financing 10
Savara Pharmaceuticals Secures USD18.54 Million in Venture Funding 10
Savara Pharma Raises US$14 Million In Series B Financing 11
Partnerships 12
Serendex Pharma Enters into Licensing Agreement with Pari Pharma 12
Equity Offering 13
Savara Prices Public Offering of Shares for USD48.9 Million 13
Savara Raises USD42.9 Million in Public Offering of Shares 14
Savara to Raise up to USD18 Million in Public Offering of Shares 15
Savara Raises USD8 Million in Public Offering of Shares and Warrants 16
Savara Raises USD21 Million in Public Offering of Shares and Warrants 17
Savara Raises USD0.9 Million in Public Offering of Shares up on Exercise of Warrants 18
Savara Raises USD30 Million in Public Offering of Shares 19
Savara Inc – Key Competitors 20
Savara Inc – Key Employees 21
Savara Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
May 09, 2018: Savara Reports First Quarter 2018 Financial Results and Provides Business Update 23
Mar 14, 2018: Savara Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update 25
Nov 08, 2017: Savara Reports Third Quarter 2017 Financial Results and Provides Business Update 27
Aug 09, 2017: Savara Reports Second Quarter 2017 Financial Results and Provides Business Update 28
Corporate Communications 29
Jan 04, 2018: Savara Announces Appointment of Peter Ginsberg as Vice President of Business Development 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Savara Inc, Medical Equipment, Key Facts, 2017 2
Savara Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Savara Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Savara Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Savara Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Savara Inc, Deals By Market, 2012 to YTD 2018 8
Savara Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Savara Pharmaceuticals Secures USD18.54 Million in Venture Funding 10
Savara Pharma Raises US$14 Million In Series B Financing 11
Serendex Pharma Enters into Licensing Agreement with Pari Pharma 12
Savara Prices Public Offering of Shares for USD48.9 Million 13
Savara Raises USD42.9 Million in Public Offering of Shares 14
Savara to Raise up to USD18 Million in Public Offering of Shares 15
Savara Raises USD8 Million in Public Offering of Shares and Warrants 16
Savara Raises USD21 Million in Public Offering of Shares and Warrants 17
Savara Raises USD0.9 Million in Public Offering of Shares up on Exercise of Warrants 18
Savara Raises USD30 Million in Public Offering of Shares 19
Savara Inc, Key Competitors 20
Savara Inc, Key Employees 21
Savara Inc, Subsidiaries 22

List of Figures
Savara Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Savara Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Savara Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Savara Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Savara Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Savara Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Savara Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Savara Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Savara Inc (SVRA):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Lycera Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Lycera Corp (Lycera) is a biopharmaceutical company that focuses on the development of oral immune modulators for the treatment of patients with autoimmune diseases and cancer. The company’s pipeline products include LYC-55716, an oral retinoic acid-related orphan receptor gamma (RORgamma) a …
  • ERG SpA (ERG):企業の財務・戦略的SWOT分析
    ERG SpA (ERG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Bayer CropScience AG:企業のM&A・事業提携・投資動向
    Bayer CropScience AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bayer CropScience AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Calavo Growers, Inc. (CVGW):企業の財務・戦略的SWOT分析
    Calavo Growers, Inc. (CVGW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • The Bank of Okinawa, Ltd. (8397):企業の財務・戦略的SWOT分析
    The Bank of Okinawa, Ltd. (8397) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • WInco Foods LLC:企業の戦略・SWOT・財務情報
    WInco Foods LLC - Strategy, SWOT and Corporate Finance Report Summary WInco Foods LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Avadel Pharmaceuticals Plc (AVDL):製薬・医療:M&Aディール及び事業提携情報
    Summary Avadel Pharmaceuticals Plc (Avadel), formerly Flamel Technologies SA is a specialty pharmaceutical company, which develops and commercializes drugs for allergy, asthma, central nervous system (CNS) (narcolepsy), pain, respiratory diseases and diabetes. The company’s products are built on its …
  • Oxford BioTherapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Oxford BioTherapeutics Ltd (OBT) is a clinical stage oncology company that develops antibody drug conjugates for the treatment of variety of cancers. The company’s product pipelines currently includes T-cell based IO therapies including check point modulators; NK cell based IO therapies such …
  • Scatec Solar ASA (SSO):電力:M&Aディール及び事業提携情報
    Summary Scatec Solar ASA (Scatec Solar) is an integrated independent producer of solar power that develops, builds, owns and operates solar power plants. It conducts project origination and development, project financing, design and engineering, procurement and construction management, operation and …
  • Sistema JSFC:企業の戦略・SWOT・財務分析
    Sistema JSFC - Strategy, SWOT and Corporate Finance Report Summary Sistema JSFC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Globe Telecom, Inc.:企業の戦略・SWOT・財務情報
    Globe Telecom, Inc. - Strategy, SWOT and Corporate Finance Report Summary Globe Telecom, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Getty Images Inc:企業の戦略的SWOT分析
    Getty Images Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Freudenberg & Co. Kommanditgesellschaft:企業の戦略・SWOT・財務分析
    Freudenberg & Co. Kommanditgesellschaft - Strategy, SWOT and Corporate Finance Report Summary Freudenberg & Co. Kommanditgesellschaft - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Main Street America Group Inc:企業の戦略的SWOT分析
    Main Street America Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Capital Power Corporation (CPX):電力:M&Aディール及び事業提携情報
    Summary Capital Power Corporation (CPC) is a power producer that develops, acquires, operates, optimizes, and builds power generation facilities. It generates electricity by harnessing energy-efficient technology from lower-carbon fuel, and a range of renewable energy sources. The company owns super …
  • Wacker Neuson Se:企業の戦略・SWOT・財務分析
    Wacker Neuson Se - Strategy, SWOT and Corporate Finance Report Summary Wacker Neuson Se - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Autolus Therapeutics Plc (AUTL):製薬・医療:M&Aディール及び事業提携情報
    Summary Autolus Therapeutics Plc (Autolus), formerly Autolus Therapeutics Limited is a clinical-stage biopharmaceutical company which offers programmed T cell immunotherapies for the treatment of hematological cancers and solid tumors. The company utilizes its T-cell programming and manufacturing te …
  • LOT Polish Airlines SA:企業の戦略・SWOT・財務情報
    LOT Polish Airlines SA - Strategy, SWOT and Corporate Finance Report Summary LOT Polish Airlines SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Symantec Corporation:企業の戦略・SWOT・財務情報
    Symantec Corporation - Strategy, SWOT and Corporate Finance Report Summary Symantec Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Fiesta Mart, Inc.:企業の戦略的SWOT分析
    Fiesta Mart, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆